Stay updated on Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Sign up to get notified when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.

Latest updates to the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page
- CheckyesterdayChange DetectedDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.4%
- Check15 days agoChange DetectedDifference0.2%
- Check22 days agoChange DetectedThe webpage has been updated to include new identifiers and indications for a clinical study involving rare cancers, while significant details about the study's design and eligibility criteria have been removed.SummaryDifference24%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.